Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USAPrajakta P. Masurkar, Meghana V. Trivedi, Ashish A. Deshmukh et al.|PharmacoEconomics|2023Cited by 25
Abstract 891: Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in the United StatesPrajakta P. Masurkar, Meghana V. Trivedi, Haluk Damgacioglu et al.|Cancer Research|2021Cited by 3